Krystal Biotech, Inc. (FRA:4KB)

Krystal Biotech Statistics

Total Valuation

Krystal Biotech has a market cap or net worth of EUR 5.96 billion. The enterprise value is 5.23 billion.

Market Cap	5.96B
Enterprise Value	5.23B

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	29.00M
Shares Outstanding	n/a
Shares Change (YoY)	+1.34%
Shares Change (QoQ)	+0.28%
Owned by Insiders (%)	11.30%
Owned by Institutions (%)	88.64%
Float	22.88M

Valuation Ratios

The trailing PE ratio is 35.15 and the forward PE ratio is 28.04.

PE Ratio	35.15
Forward PE	28.04
PS Ratio	18.74
PB Ratio	6.14
P/TBV Ratio	6.14
P/FCF Ratio	42.22
P/OCF Ratio	39.68
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 38.02, with an EV/FCF ratio of 37.06.

EV / Earnings	30.85
EV / Sales	16.42
EV / EBITDA	38.02
EV / EBIT	38.70
EV / FCF	37.06

Financial Position

The company has a current ratio of 10.14, with a Debt / Equity ratio of 0.01.

Current Ratio	10.14
Quick Ratio	9.43
Debt / Equity	0.01
Debt / EBITDA	0.06
Debt / FCF	0.06
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 19.66% and return on invested capital (ROIC) is 9.70%.

Return on Equity (ROE)	19.66%
Return on Assets (ROA)	8.91%
Return on Invested Capital (ROIC)	9.70%
Return on Capital Employed (ROCE)	13.78%
Revenue Per Employee	1.16M
Profits Per Employee	616,476
Employee Count	275
Asset Turnover	0.34
Inventory Turnover	0.76

Taxes

Income Tax	-10.19M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.76% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+25.76%
50-Day Moving Average	178.76
200-Day Moving Average	144.33
Relative Strength Index (RSI)	58.75
Average Volume (20 Days)	2

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.17

Income Statement

In the last 12 months, Krystal Biotech had revenue of EUR 318.05 million and earned 169.53 million in profits. Earnings per share was 5.68.

Revenue	318.05M
Gross Profit	299.80M
Operating Income	134.96M
Pretax Income	159.34M
Net Income	169.53M
EBITDA	136.09M
EBIT	134.96M
Earnings Per Share (EPS)	5.68

Balance Sheet

The company has 623.09 million in cash and 8.11 million in debt, giving a net cash position of 728.44 million.

Cash & Cash Equivalents	623.09M
Total Debt	8.11M
Net Cash	728.44M
Net Cash Per Share	n/a
Equity (Book Value)	969.81M
Book Value Per Share	33.46
Working Capital	711.14M

Cash Flow

In the last 12 months, operating cash flow was 150.18 million and capital expenditures -9.05 million, giving a free cash flow of 141.13 million.

Operating Cash Flow	150.18M
Capital Expenditures	-9.05M
Free Cash Flow	141.13M
FCF Per Share	n/a

Margins

Gross margin is 94.26%, with operating and profit margins of 42.43% and 53.30%.

Gross Margin	94.26%
Operating Margin	42.43%
Pretax Margin	50.10%
Profit Margin	53.30%
EBITDA Margin	42.79%
EBIT Margin	42.43%
FCF Margin	44.37%

Dividends & Yields

Krystal Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.34%
Shareholder Yield	-1.34%
Earnings Yield	2.84%
FCF Yield	2.37%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Krystal Biotech has an Altman Z-Score of 28.67 and a Piotroski F-Score of 6.

Altman Z-Score	28.67
Piotroski F-Score	6